Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599845 | 0.83 | DAO (0.47) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL14701887 | 0.81 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7594844 | 0.81 | DAO (0.49) | DAOPOLBKMT2A | |
| SCHEMBL11431122 | 0.80 | DAO (0.60) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL10296643 | 0.80 | DAO (0.51) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL6648995 | 0.80 | MEN1 (0.47) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL444120 | 0.79 | DAO (0.58) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL792991 | 0.77 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL11691177 | 0.77 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A | |
| SCHEMBL7596452 | 0.77 | DAO (0.56) | DAOPOLBMEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57149277-A | — | — | None | — | — | JP | disclosed |
| US-7612065-B2 | Inhibitors of c-JUN N-terminal kinases (JNK) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | SALITURO FRANCESCO G | 2008-02-07 | — | — | US | disclosed |
| JP-S57149277-A | HETEROCYCLIC COMPOUND | TAIHO YAKUHIN KOGYO KK | 1982-09-14 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033022-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) | MAP3K1, JUN, MAP3K7 | DAO 2689/4885POLB 2623/4885MEN1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.